nNOS U.S., a subsidiary of Beyond Air (XAIR), was granted FDA orphan designation for its treatment of malignant glioma, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Beyond Air signs international LungFit PH distribution agreements
- Beyond Air’s Earnings Call Highlights Growth and Challenges
- Beyond Air: Strong Revenue Growth and Strategic Partnerships Drive Buy Rating
- Beyond Air price target lowered to $5 from $20 at Piper Sandler
- Beyond Air Reports Strong Revenue Growth in Q1 2026